[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin, 2022; 72, 7−33. doi:  10.3322/caac.21708
[2] Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl), 2021; 134, 783−91. doi:  10.1097/CM9.0000000000001474
[3] Rebbeck TR. Biomarkers of inherited susceptibility and cancer. IARC Sci Publ, 2004; 91−103.
[4] NIHR Global Health Research Unit on Global Surgery. Quality and outcomes in global cancer surgery: protocol for a multicentre, international, prospective cohort study (GlobalSurg 3). BMJ Open, 2019; 9, e026646. doi:  10.1136/bmjopen-2018-026646
[5] Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol, 2012; 2, 98.
[6] Prasad DVR, Richards S, Mai XM, et al. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity, 2003; 18, 863−73. doi:  10.1016/S1074-7613(03)00147-X
[7] Sica GL, Choi IH, Zhu GF, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity, 2003; 18, 849−61. doi:  10.1016/S1074-7613(03)00152-3
[8] Zang XX, Loke P, Kim J, et al. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA, 2003; 100, 10388−92. doi:  10.1073/pnas.1434299100
[9] Li MX, Che N, Feng Y, et al. B7-H4 expression promotes non-small cell lung cancer progression via AMPK/mTOR signaling. Exp Mol Pathol, 2022; 125, 104755. doi:  10.1016/j.yexmp.2022.104755
[10] Wang JK, Wang Z, Li GD. MicroRNA-125 in immunity and cancer. Cancer Lett, 2019; 454, 134−45. doi:  10.1016/j.canlet.2019.04.015
[11] Hudson TJ. Wanted: regulatory SNPs. Nat Genet, 2003; 33, 439−40. doi:  10.1038/ng0403-439
[12] El Din GS, Youness RA, Assal RA, et al. MiRNA-506-3p directly regulates rs10754339 (A/G) in the immune checkpoint protein B7-H4 in breast cancer. Microrna, 2020; 9, 346−53.
[13] Lehmann TP, Korski K, Ibbs M, et al. Rs12976445 variant in the pri-miR-125a correlates with a lower level of hsa-miR-125a and ERBB2 overexpression in breast cancer patients. Oncol Lett, 2013; 5, 569−73. doi:  10.3892/ol.2012.1040
[14] Zhang J, Zhang MY, Jiang W, et al. B7-H4 gene polymorphisms are associated with sporadic breast cancer in a Chinese Han population. BMC Cancer, 2009; 9, 394. doi:  10.1186/1471-2407-9-394
[15] Li DL, Zhang J, Fu ZK, et al. Association between polymorphisms of B7-H4 gene and the risk of sporadic breast cancer in Heilongjiang Province. Cancer Res Clin, 2009; 21, 232−5. (In Chinese
[16] Özgöz A, Samli H, Öztürk KH, et al. An investigation of the effects of FGFR2 and B7-H4 polymorphisms in breast cancer. J Cancer Res Ther, 2013; 9, 370−5. doi:  10.4103/0973-1482.114434
[17] Tsai SM, Wu SH, Hou MF, et al. The immune regulator VTCN1 gene polymorphisms and its impact on susceptibility to breast cancer. J Clin Lab Anal, 2015; 29, 412−8. doi:  10.1002/jcla.21788
[18] Özgöz A, Şamli M, Dinçel D, et al. Association of B7-H4 gene polymorphisms in urothelial bladder cancer. Turk J Med Sci, 2017; 47, 443−6. doi:  10.3906/sag-1603-54
[19] Sadeghi H, Nazemalhosseini-Mojarad E, Yaghoob-Taleghani M, et al. MiR-30a promoter variation contributes to the increased risk of colorectal cancer in an Iranian population. J Cell Biochem, 2019; 120, 7734−40. doi:  10.1002/jcb.28047
[20] Damodaran M, Paul SFD, Venkatesan V. Genetic polymorphisms in miR-146a, miR-196a2 and miR-125a genes and its association in prostate cancer. Pathol Oncol Res, 2020; 26, 193−200. doi:  10.1007/s12253-018-0412-x
[21] Hakimian M, Ghorbian S. Negative associations between the has-miR-27a and hsa-miR-125a gene variations and prostate cancer susceptibility. Mol Biol Rep, 2020; 47, 4209−14. doi:  10.1007/s11033-020-05548-7
[22] Lehmann TP, Miskiewicz J, Szostak N, et al. In vitro and in silico analysis of miR-125a with rs12976445 polymorphism in breast cancer patients. Appl Sci (Basel), 2020; 10, 7275. doi:  10.3390/app10207275
[23] Sun JS. Association between MicroRNA-125a rs12976445 polymorphism and lung cancer susceptibility in Northeast Chinese population. China Medical University. 2021. (In Chinese)
[24] Thorlund K, Wetterslev J, Brok J, et al. User manual for trial sequential analysis (TSA). Cent Clin Interv Res, 2011; 1−115.
[25] Lu XL, Liu MT, Liao YX, et al. Meta-analysis of the association between mTORC1-related genes polymorphisms and cancer risk. Pathol Res Pract, 2022; 229, 153696. doi:  10.1016/j.prp.2021.153696
[26] Yu YH, Mao LP, Cheng ZN, et al. A novel regQTL-SNP and the risk of lung cancer: a multi-dimensional study. Arch Toxicol, 2021; 95, 3815−27. doi:  10.1007/s00204-021-03170-5